Abeona Therapeut Financials
This page shows Abeona Therapeut (ABEO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Abeona’s visible operating mechanic is development-stage cash burn sustained by balance-sheet replenishment, not by current revenue.
Cash increased to$78.4M even as free cash flow was-$84.3M , so the larger cash balance came from outside operations rather than from the business turning self-funding. That is consistent with capital-structure repair: shares outstanding roughly doubled while debt-to-equity fell from 3.3x to 0.05x, meaning liquidity improved by issuing capital instead of leaning on debt.
Near-term liquidity looks ample because cash of
Gross margin of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Abeona Therapeut's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Abeona Therapeut scores -1.66, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($344.8M) relative to total liabilities ($60.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Abeona Therapeut passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Abeona Therapeut generates $1.07 in operating cash flow (-$76.3M OCF vs -$71.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Abeona Therapeut earns $-23.9 in operating income for every $1 of interest expense (-$89.4M vs $3.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Abeona Therapeut generated $5.8M in revenue in fiscal year 2025.
Abeona Therapeut's EBITDA was -$86.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 39.7% from the prior year.
Abeona Therapeut reported -$71.2M in net income in fiscal year 2025. This represents a decrease of 211.7% from the prior year.
Abeona Therapeut earned $1.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 165.2% from the prior year.
Cash & Balance Sheet
Abeona Therapeut generated -$84.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 44.2% from the prior year.
Abeona Therapeut held $78.4M in cash against $7.8M in long-term debt as of fiscal year 2025.
Abeona Therapeut had 55M shares outstanding in fiscal year 2025. This represents an increase of 20.6% from the prior year.
Margins & Returns
Abeona Therapeut's gross margin was 73.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Abeona Therapeut's operating margin was -1536.9% in fiscal year 2025, reflecting core business profitability.
Abeona Therapeut's net profit margin was -1223.1% in fiscal year 2025, showing the share of revenue converted to profit.
Abeona Therapeut's ROE was -44.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 189.5 percentage points from the prior year.
Capital Allocation
Abeona Therapeut invested $26.8M in research and development in fiscal year 2025. This represents a decrease of 22.0% from the prior year.
Abeona Therapeut invested $8.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 226.0% from the prior year.
ABEO Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.7M | N/A | N/A | $400K | N/A | N/A | N/A | N/A |
| Cost of Revenue | $2.7M | N/A | $488K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $6.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $9.6M | N/A | $4.2M-29.1% | $5.9M-40.2% | $9.9M | N/A | $8.9M-3.0% | $9.2M |
| SG&A Expenses | $19.5M | N/A | $19.3M+12.6% | $17.1M+75.2% | $9.8M | N/A | $6.4M-25.9% | $8.6M |
| Operating Income | -$23.0M | N/A | -$24.0M-5.4% | -$22.8M-15.5% | -$19.7M | N/A | -$15.3M+14.1% | -$17.9M |
| Interest Expense | $830K | N/A | $901K-5.9% | $957K-4.1% | $998K | N/A | $1.1M+2.8% | $1.1M |
| Income Tax | $2K | N/A | -$15.2M-198.0% | $15.5M | N/A | N/A | N/A | N/A |
| Net Income | -$17.1M | N/A | -$5.2M-104.7% | $108.8M+1004.8% | -$12.0M | N/A | -$30.3M-508.7% | $7.4M |
| EPS (Diluted) | $-0.30 | N/A | $-0.10-105.8% | $1.71+812.5% | $-0.24 | N/A | $-0.63-142.3% | $-0.26 |
ABEO Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $198.5M-9.6% | $219.6M-5.0% | $231.1M-6.1% | $246.2M+147.8% | $99.4M-8.8% | $108.9M-9.7% | $120.6M-10.0% | $134.0M |
| Current Assets | $183.0M-10.7% | $204.9M-5.2% | $216.1M-6.9% | $232.3M+163.6% | $88.1M-12.6% | $100.9M-10.5% | $112.7M-10.5% | $125.9M |
| Cash & Equivalents | $61.4M-21.8% | $78.4M-5.4% | $82.9M-49.3% | $163.5M+926.2% | $15.9M-31.8% | $23.4M+48.5% | $15.7M-54.3% | $34.4M |
| Inventory | $6.1M+10.2% | $5.5M+13.3% | $4.8M+80.6% | $2.7M | N/A | N/A | N/A | N/A |
| Accounts Receivable | $6.2M+0.9% | $6.1M | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $53.6M-11.3% | $60.4M+0.8% | $59.9M-27.6% | $82.7M+42.6% | $58.0M-10.7% | $64.9M-13.3% | $74.8M+23.1% | $60.8M |
| Current Liabilities | $31.0M+5.0% | $29.6M+33.3% | $22.2M-35.7% | $34.5M+91.9% | $18.0M+8.4% | $16.6M-10.0% | $18.4M+9.4% | $16.8M |
| Long-Term Debt | $4.8M-39.2% | $7.8M-28.1% | $10.9M-22.4% | $14.0M+25.7% | $11.1M-14.6% | $13.0M-8.2% | $14.2M-11.9% | $16.1M |
| Total Equity | $144.9M-9.0% | $159.2M-7.0% | $171.2M+4.7% | $163.6M+295.1% | $41.4M-6.0% | $44.0M-3.8% | $45.8M-37.5% | $73.2M |
| Retained Earnings | -$759.1M-2.3% | -$742.1M-2.8% | -$721.6M-0.7% | -$716.5M+13.2% | -$825.3M-1.5% | -$813.3M-1.2% | -$804.0M-3.9% | -$773.7M |
ABEO Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.8M-10.3% | -$18.0M+15.3% | -$21.2M-12.8% | -$18.8M-2.1% | -$18.4M-11.1% | -$16.6M-35.4% | -$12.2M+3.5% | -$12.7M |
| Capital Expenditures | $935K-18.9% | $1.2M-54.2% | $2.5M-13.1% | $2.9M+107.1% | $1.4M+131.2% | $606K+50.0% | $404K-43.2% | $711K |
| Free Cash Flow | -$20.7M-8.5% | -$19.1M+19.4% | -$23.7M-9.3% | -$21.7M-9.5% | -$19.8M-15.4% | -$17.2M-35.8% | -$12.6M+5.7% | -$13.4M |
| Investing Cash Flow | $5.0M-48.1% | $9.6M+114.8% | -$64.6M-141.5% | $155.9M+3600.2% | $4.2M-77.7% | $18.9M+406.1% | -$6.2M+86.0% | -$44.1M |
| Financing Cash Flow | -$2.2M-161.5% | $3.6M-30.0% | $5.2M-50.8% | $10.5M+55.1% | $6.8M+27.4% | $5.3M+1877.3% | -$299K-100.4% | $73.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ABEO Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -264.1% | N/A | N/A | -5698.0% | N/A | N/A | N/A | N/A |
| Net Margin | -195.8% | N/A | N/A | 27208.3% | N/A | N/A | N/A | N/A |
| Return on Equity | -11.8% | N/A | -3.0%-69.5pp | 66.5%+95.6pp | -29.1% | N/A | -66.1%-76.2pp | 10.1% |
| Return on Assets | -8.6% | N/A | -2.2%-46.4pp | 44.2%+56.3pp | -12.1% | N/A | -25.1%-30.6pp | 5.5% |
| Current Ratio | 5.89-1.0 | 6.93-2.8 | 9.74+3.0 | 6.73+1.8 | 4.90-1.2 | 6.08-0.0 | 6.12-1.4 | 7.48 |
| Debt-to-Equity | 0.03-0.0 | 0.05-0.0 | 0.06-0.0 | 0.09-0.2 | 0.27-0.0 | 0.30-0.0 | 0.31+0.1 | 0.22 |
| FCF Margin | -237.8% | N/A | N/A | -5421.3% | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Abeona Therapeut's annual revenue?
Abeona Therapeut (ABEO) reported $5.8M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Abeona Therapeut profitable?
No, Abeona Therapeut (ABEO) reported a net income of -$71.2M in fiscal year 2025, with a net profit margin of -1223.1%.
What is Abeona Therapeut's EBITDA?
Abeona Therapeut (ABEO) had EBITDA of -$86.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Abeona Therapeut have?
As of fiscal year 2025, Abeona Therapeut (ABEO) had $78.4M in cash and equivalents against $7.8M in long-term debt.
What is Abeona Therapeut's gross margin?
Abeona Therapeut (ABEO) had a gross margin of 73.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Abeona Therapeut's operating margin?
Abeona Therapeut (ABEO) had an operating margin of -1536.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Abeona Therapeut's net profit margin?
Abeona Therapeut (ABEO) had a net profit margin of -1223.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Abeona Therapeut's return on equity (ROE)?
Abeona Therapeut (ABEO) has a return on equity of -44.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Abeona Therapeut's free cash flow?
Abeona Therapeut (ABEO) generated -$84.3M in free cash flow during fiscal year 2025. This represents a -44.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Abeona Therapeut's operating cash flow?
Abeona Therapeut (ABEO) generated -$76.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Abeona Therapeut's total assets?
Abeona Therapeut (ABEO) had $219.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Abeona Therapeut's capital expenditures?
Abeona Therapeut (ABEO) invested $8.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Abeona Therapeut spend on research and development?
Abeona Therapeut (ABEO) invested $26.8M in research and development during fiscal year 2025.
What is Abeona Therapeut's current ratio?
Abeona Therapeut (ABEO) had a current ratio of 6.93 as of fiscal year 2025, which is generally considered healthy.
What is Abeona Therapeut's debt-to-equity ratio?
Abeona Therapeut (ABEO) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Abeona Therapeut's return on assets (ROA)?
Abeona Therapeut (ABEO) had a return on assets of -32.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Abeona Therapeut's cash runway?
Based on fiscal year 2025 data, Abeona Therapeut (ABEO) had $78.4M in cash against an annual operating cash burn of $76.3M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Abeona Therapeut's Altman Z-Score?
Abeona Therapeut (ABEO) has an Altman Z-Score of -1.66, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Abeona Therapeut's Piotroski F-Score?
Abeona Therapeut (ABEO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Abeona Therapeut's earnings high quality?
Abeona Therapeut (ABEO) has an earnings quality ratio of 1.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Abeona Therapeut cover its interest payments?
Abeona Therapeut (ABEO) has an interest coverage ratio of -23.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Abeona Therapeut?
Abeona Therapeut (ABEO) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.